2023-12-11
Heta Stolen - Gabather
Michael-Robin Witt, CEO, enlightens potential partnerships based on preliminary study
results of their drug candidate GT-002.
Witt highlighted plans for GT-002, aiming for development and
commercialization post-Phase 2 studies, and concluded by outlining Gabather's main objectives for 2024.
He also comments the ongoing rights issue where they raise 28.6 MSEK.
Läs mer